(Total Views: 263)
Posted On: 04/24/2018 12:27:11 PM
Post# of 72447
I don't think that there would be a significant difference in the number of patients who would be treated with Bril-OM, no matter who markets it.
There is NO other treatment for oral mucositis.
Every oncologist who did NOT prescribe this for patients at high risk of oral mucositis could be subject to a malpractice lawsuit.
A few well-placed TV ads alerting patients to the possibility that they might get OM, and that there was an easy-to-use oral rinse to prevent it -- everyone who sees the ad is going to alert their loved ones to it.
So I think it is UNreasonable to think that a big pharma would reach 5 times as many patients as IPIX would on its own. Maybe a small percentage fewer patients, but certainly not 1/5 as many.
There are only so many oncologists and oncology clinics/hospitals. It would not be hard to reach them all with information about Bril-OM.
There is NO other treatment for oral mucositis.
Every oncologist who did NOT prescribe this for patients at high risk of oral mucositis could be subject to a malpractice lawsuit.
A few well-placed TV ads alerting patients to the possibility that they might get OM, and that there was an easy-to-use oral rinse to prevent it -- everyone who sees the ad is going to alert their loved ones to it.
So I think it is UNreasonable to think that a big pharma would reach 5 times as many patients as IPIX would on its own. Maybe a small percentage fewer patients, but certainly not 1/5 as many.
There are only so many oncologists and oncology clinics/hospitals. It would not be hard to reach them all with information about Bril-OM.
(2)
(1)
